ci top pick best idea stori rel straightforward
follow somewhat tumultu fill extern nois
think continu oper execut drive multipl expans ci track
toward target adj ep think risk/reward attract share
trade adj ep
continu believ long-term valu own integr pbm
manag care asset think share price appreci primarili driven
continu oper execut compani track target adj
ep expect y/i adj oper incom growth toward higher end
manag target rang annual impact suppli chain initi
benefit comp help off-set wind strand fix cost relat
think ci healthcar services-focus model uniqu differenti
pursu competitor given emphasi specialti pharmaci growth
drug trend driven specialti valu pbm capabl primarili
manag specialti rather tradit drug think express script well
posit manag specialti trend next sever year industry-lead
specialti pharmaci capabl accredo
beyond think market fulli appreci ci abil deploy capit ci
expect growth capit given focu pay debt
estim growth capit could increas think could upsid
share repurchas estim even assum meaning dividend
notabl upcom catalyst includ potenti sale ci group disabl life
busi opportun increment capit deploy legisl carri
hif suspens democrat nation convent presidenti elect
rais price target updat price target impli upsid
current level price target impli price-to-earnings multipl adj
potenti risk call includ unexpect rise medic cost trend issu
transit ci pharmaci membership onto express script platform election-
relat risk think could also headlin risk legislation/polici propos
elimin rebat spread price note compon
price pbm servic
pleas see page report import disclosur
posit share ci believ acquisit esrx posit compani
succeed evolv healthcar landscap stand-alone basi ci carv
strong posit market particularli aso recent result demonstr abil
deliv strong result led critic compani spend billion
acquir esrx reflect rel depress valuat compar peer
believ unwarr believ investor may give enough credit near-
term growth opportun yet outlin beyond million cost synergi
greater purchas scale esrx ci posit full-risk aso
market believ strateg valu esrx even potenti near-
term accret lie long-term posit market shift toward greater care
coordin value-bas care
oper earn grow y/i
grow y/i
stronger expect medic custom
realiz pre-tax cost synergi excess
integr challeng lower
expect synergi esrx deal
global health servic compani subsidiari offer medic dental
disabl life accid insur relat product servic
product servic offer employ group select
intern market offer supplement health life accid insur product
intern health care coverag servic busi government non-
government organ individu decemb acquir
script largest pharmaci benefit manag script servic includ
drug util review formulari manag diseas manag medic drug
data analysi servic medic inform manag servic oper five
segment integr medic intern market oper
corpor
ci best idea think stori rel straightforward
follow somewhat tumultu fill headlin polit risk
legisl risk skeptic long-term viabil pbm busi model
oper perform manag deliv commit
posit y/i adj oper incom growth put
rest concern pbm busi declin challeng larg
rearview mirror think appreci primarili driven multipl
expans reflect continu oper execut compani track
target adj ep
see growth driven continu execut core integr medic
divis ex-hif potenti upsid come expect
adj oper incom growth toward higher end manag target
rang annual impact suppli chain initi benefit comp
help off-set wind strand fix cost relat addit
compani expect avail growth capit pay debt
use return sharehold believ major
growth capit like alloc share repurchas next year given
manag prefer warehous signific quantiti cash
beyond expect start benefit cross-sel effort see
minim revenu synergi expect cross-sel effort could build
posit momentum year progress benefit
beyond exampl manag highlight sever new innov either
acceler directli enabl result combin
safeguardrx embarc expect first time compani
approach health plan employ sell season coordin offer
greater emphasi cross-sel look updat sell season
gener believ harder win medic custom pharmaci
custom expect near-term cross-sel opportun focu
carving-in tradit pharmaci ci medic custom cross-sal accredo
specialti pharmaci servic sell ci specialti program behavior dental
legaci express script client
ci signific capit deploy option head reach
target leverag ratio base compani expect
oper cash flow assum debt paydown capital-expenditure
estim ci could least avail growth capit meet
manag novemb indic us manag open
idea higher dividend though near-term believ implement
higher dividend would well receiv market would open compani
new investor base would support stock dividend yield
current base ltm compar
think compani would like target dividend yield closer in-lin
peer group long-term estim annual dividend would
bring dividend yield base price target even assum
dividend payment would still leav capit avail share
repurchas lead us believ share repurchas estim
could prove conserv estim increment share buyback could add
adj ep estim give us greater comfort manag
abil achiev adj ep target
ci pharmaci servic model come life
think ci healthcar services-focus model uniqu differenti
pursu competitor given greater emphasi place specialti
pharmaci specialti drug cost one biggest pain point employ higher
specialti drug cost third frequent cite driver increas
medic cost trend septemb employ cost trend survey believ
effect care coordin enhanc combin pharmaci medic
data given pharmaci typic first-lin often prevent treatment
resort costli medic care accord iqvia specialti
compris nearli total drug spend grown
compound-annual-growth-rate contrast tradit drug spend declin
compound-annual-growth-rate think express script well posit manag specialti trend
next sever year industry-lead specialti pharmaci capabl
accredo specialti spend continu grow new high-cost gene
therapi come market think potenti valu proposit combin
compani could compel new exist client beyond near- medium-
term believ strateg valu express script lie long-term
posit employ focu continu trend toward manag total cost care
rather manag medic pharmaci spend separ benefit
potenti sale disabl life busi could neutral adj ep
reuter report summer compani explor sale group
disabl life busi could fetch recent report
wall street journal suggest agreement could reach year-end
estim group disabl segment contribut adj ep
assum after-tax proce potenti sale plow
asr estim neutral impact adj ep howev think impact
asr could pronounc potenti result
accret current adj ep estim
investor focu ci abil anoth big deal
believ larg scale like least near- medium-term
manag indic prefer smaller tuck-in deal note deal
accret import element evalu criteria would suggest
deal compani would problemat stage given multipl
dispar two compani ci trade adj ep vs
addit ci express comfort current asset portfolio confid
abil deliv annual membership growth medicar advantag
membership growth expect toward lower-end rang
acceler beyond think manag would feel compel
deal ci struggl achiev growth target medicar advantag howev
manag also note prefer buy asset demonstr
abil deliv consist organ growth
believ expect avail growth capit
alloc share repurchas howev think could opportun
increment buyback next year ci divest group disabl life busi
could sell accord recent report assum compani would
like use proce potenti sale initi asr order minim
impact adj ep assum net proce plow asr
estim approxim neutral ep impact lower share count essenti offset
lower earn els equal estim would increas adj ep
estim
believ manag could potenti rais dividend base
price target estim ci would pay dividend
annual dividend share yield indic believ
ci could least growth capit avail share repurchas
and/or dividend assum dividend payment still leav
capit avail share repurchas believ share
repurchas estim could prove conserv would repres increment
sourc upsid adj ep project
ci less hif exposur peer given greater mix commerci aso
membership hif still repres meaning headwind estim non-
deduct portion hif repres headwind
believ continu resolut cr bill anoth spend bill like
vehicl carri hif repeal current cr set expir decemb
congress final year-end spend packag believ lawmak could
pass anoth cr would fund govern januari congress
reach agreement long-term spend packag end januari
believ would agre anoth cr would fund feder govern
novemb elect believ hif could attach one
packag note hif-holiday benefici manag care compani
larg medicar advantag commerci book expect compani
invest portion hif-holiday enhanc medicar advantag benefit
order improv competit product
expect manag care group less sensit polit rhetor
given worst case polici scenario alreadi propos would
surpris increas volatil around democrat nation
convent juli depend variou candid poll stock
react posit centrist candid biden emerg nomine
reaction like neg progress candid emerg
elizabeth warren think medicare-for-al virtual chanc pass
law expect investor posit potenti higher risk environ
payer provid far-left candid emerg nomine
think texa case could also caus volatil await decis
circuit think case ultim end suprem court
note ci third lowest exposur percentag adj ep
rel peer group
increas price target roll five-year
discount cash flow analysi updat price target impli upsid
current level maintain adj ep estim
adj ep increas price target impli price-to-earnings multipl
adj ep estim target multipl still repres discount peer
group averag would expect see multipl expand time compani
success execut strategi see potenti upsid price target
believ manag adj ep guidanc prove conserv
think ci realiz cost synergi manag expect million
note adj ep estim doesnt incorpor potenti revenu
thomson eikon cowen compani
use five-year discount cash flow analysi primari valuat method
deriv price target assum discount rate termin
growth rate believ discount rate assumpt could view conserv
rel actual weight averag cost capit view assumpt
reason rate long run addit believ impli equiti
valu dcf could prove conserv excess cash calcul cash less total
debt contempl parent compani cash conserv way
calcul excess cash secondari measur look forward price-to-earnings multipl
impli dcf analysi compar histor averag
uptick medic trend medic cost trend mute
past year uptick underli medic cost may difficult
predict product price within commerci medicar market
integr risk integr express script track well far
repres potenti risk particularli compani transit ci
pharmaci membership optumrx onto express script platform
compani expect fulli transit annual script
end
polit risk see potenti downsid risk manag care stock
depend candid becom democrat nomine biden
propos strengthen posit nomine
manag care group far-left candid berni sander
elizabeth warren would view neg
million except per-shar data
cowen compani
model assumptionstermin growth tax depreci chang work terminal- capit valuefre pv npv free npv futur excess valu total number valu per year end decemb cowen
million except per-shar data
cowen compani
invest cost benefit expens servic pharmaci oper non-control interest incom pre-tax adjust oper net non-control interest incom incom adjust oper share outstand fulli net incom reconcili net chang servic pre-tax incom end decemb cowen
million except per-shar data
compani report cowen compani
invest cost benefit expens servic pharmaci oper non-control interest incom pre-tax adjust oper net non-control interest incom loss adjust incom adjust oper share outstand fulli net incom reconcili amort acquir intang realiz gain chang y/i invest cost benefit servic pre-tax incom cowen
million except per-shar data
compani report cowen compani
invest loss ratio loss ratio expens revenu revenu oper oper oper adjust oper pre-tax incom reconcili amort acquir intang realiz gain chang y/i premium invest oper cowen
million except per-shar data
compani report cowen compani
invest servic pharmaci profit revenu expens oper adjust oper pre-tax incom reconcili amort acquir intang realiz gain chang y/i pharmaci invest servic oper cowen
million except per-shar data
compani report cowen compani
invest cost benefit expens oper expens interest incom oper adjust oper pre-tax incom reconcili amort acquir intang realiz gain itemsnon-control chang y/i invest cost benefit oper cowen
million except per-shar data
compani report cowen compani
invest cost benefit expens oper interest incom oper adjust oper pre-tax incom reconcili amort acquir intang realiz gain itemsnon-control chang y/i invest cost benefit oper cowen
million
compani report cowen compani
receiv current polici acquisit tax asset asset account insur contracthold servic cost expens insur contracthold tax liabil non-curr account non-controlling equitycommon paid comprehens treasuri stock sharehold liabil sharehold liquid ratio current receiv claim payabl structur long-term solvenc ratio return invest capit averag total asset averag stockhold equiti end decemb cowen
million
compani report cowen compani
invest gain incom extinguish chang asset liabil net non-oper effect account polici acquisit servic cost payabl accru expens oper net cash equip purchas invest repay debt common common foreign currenc rate chang cash cash increas decreas end decemb cowen
million
compani report cowen compani
invest gain loss incom tax benefit extinguish chang asset liabil net non-oper effect account polici acquisit servic cost payabl accru expens oper invest sold fix matur equiti matur repay fix matur equiti sale matur purchas fix matur equiti primarili short-term equip net cash invest interest credit contracthold deposit benefit payment contracthold deposit chang short-term debt long-term proce issuanc long-term common common financ foreign currenc rate chang cash cash increas decreas cowen
valu manag care stock use pe multipl forward earn manag care
sector trade averag forward year earn past year
peak trough troubl econom time
frame given reform-rel multi-year top-lin growth prospect believ sector
trade high end recent histor valuat
success individu public exchang remain consider question mark
head third year program final year two three premium
stabil program reinsur risk corridor although exchang profit
expect improv expect continu money lose enterpris
industri particip receipt risk corridor payment remain potenti threat
success compani reli receiv medicar advantag payment
reduct includ potenti introduct new risk adjust model could
reduc futur medicar advantag margin growth prospect rel expect
gener medicaid payment expans popul gener
howev mount evid state like reduc payment level
medic cost trend mute past year uptick underli
medic cost may difficult predict product price within commerci
integr esrx anoth potenti risk particularli compani eventu move
ci live onto esrx platform also begin march began transit
membership pbm ingeniorx support disrupt could
impact ci note esrx tsa run
transit work move would need negoti
potenti propos hh regard futur rebat could impact ci
would expect potenti impact headlin risk vs meaning impact
remain chanc administr could propos sweep broad new
